Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Durect Corp (DRRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,039
  • Shares Outstanding, K 162,360
  • Annual Sales, $ 18,560 K
  • Annual Income, $ -25,320 K
  • 60-Month Beta 2.02
  • Price/Sales 6.50
  • Price/Cash Flow N/A
  • Price/Book 8.40
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.15
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/07/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.05
  • Number of Estimates 3
  • High Estimate -0.04
  • Low Estimate -0.05
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.52 +43.37%
on 04/26/19
0.90 -17.17%
on 05/06/19
+0.17 (+28.47%)
since 04/17/19
3-Month
0.52 +43.37%
on 04/26/19
0.90 -17.17%
on 05/06/19
+0.01 (+0.74%)
since 02/15/19
52-Week
0.46 +62.07%
on 12/28/18
2.25 -66.87%
on 06/11/18
-1.22 (-62.16%)
since 05/17/18

Most Recent Stories

More News
DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer, and Michael H. Arenberg, Chief Financial Officer, will be participating in the 20th Annual B. Riley FBR Institutional...

DRRX : 0.75 (unch)
DURECT Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 8, 2019 / DURECT Corp. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 8:30 AM Eastern Time.

DRRX : 0.75 (unch)
Durect: 1Q Earnings Snapshot

CUPERTINO, Calif. (AP) _ Durect Corp. (DRRX) on Tuesday reported a loss of $7.1 million in its first quarter.

DRRX : 0.75 (unch)
DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial

DURECT Corporation (Nasdaq: DRRX) today announced preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) Phase 2a clinical trial. On Wednesday, May 8th at 8:30 a.m. Eastern Time, DURECT will...

DRRX : 0.75 (unch)
DURECT Corporation Announces First Quarter 2019 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2019 and provided a corporate update, including preliminary data from the ongoing DUR-928 Phase...

DRRX : 0.75 (unch)
DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial Results

DURECT Corporation (Nasdaq: DRRX) today announced that it will report preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) trial and its financial results for the three months ended March...

DRRX : 0.75 (unch)
DURECT Appoints Two New Board Members

DURECT Corporation (Nasdaq: DRRX) announced today the appointment of two new members to its board of directors. Dr. Gail M. Farfel, Executive Vice President and Chief Development Officer of Zogenix, Inc.,...

DRRX : 0.75 (unch)
AERI : 39.06 (-3.65%)
ZGNX : 37.39 (-0.82%)
Analysis: Positioning to Benefit within The Allstate, Seattle Genetics, Intra-Cellular Therapies, AMN Healthcare Services, AVX, and DURECT -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Allstate Corporation (NYSE:ALL),...

ALL : 95.64 (-0.24%)
AMN : 50.27 (-0.69%)
ITCI : 12.51 (+0.56%)
AVX : 15.29 (-2.36%)
DRRX : 0.75 (unch)
SGEN : 66.42 (+0.61%)
AHS : 33.02 (-1.31%)
Transdermal/Transmucosal Drug Delivery System Market Size, Growth Opportunities, Trends by Manufacturers, Regions, Application & Forecast to 2024

Market Study Report newly added the Global Transdermal/Transmucosal Drug Delivery System Market Report that gives meticulous investigation of current scenario of the market size, share, demand, growth,...

DRRX : 0.75 (unch)
ATRS : 2.81 (-1.40%)
CORI : 12.68 (+0.24%)
ZSAN : 3.01 (-1.63%)
DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASH

DURECT Corporation (Nasdaq: DRRX) announced today that Michael Arenberg, Chief Financial Officer, will be presenting at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9 at 10:50...

DRRX : 0.75 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade DRRX with:

Business Summary

Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from...

See More

Key Turning Points

2nd Resistance Point 0.81
1st Resistance Point 0.78
Last Price 0.75
1st Support Level 0.70
2nd Support Level 0.66

See More

52-Week High 2.25
Fibonacci 61.8% 1.57
Fibonacci 50% 1.36
Fibonacci 38.2% 1.14
Last Price 0.75
52-Week Low 0.46

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar